Feedback

The effects of levosimendan in patients undergoing transcatheter aortic valve replacement- a retrospective analysis

Affiliation
State Key Laboratory of Cardiovascular Disease ,Department of Cardiology ,Fuwai Hospital ,National Center for Cardiovascular Disease ,Chinese Academy of Medical Science and Peking Union Medical College ,Beijing ,China
Zhao, Zhenyan;
Affiliation
State Key Laboratory of Cardiovascular Disease ,Department of Cardiology ,Fuwai Hospital ,National Center for Cardiovascular Disease ,Chinese Academy of Medical Science and Peking Union Medical College ,Beijing ,China
Meng, Zhen;
Affiliation
Interventional Center of Valvular Heart Disease ,Beijing Anzhen Hospital ,Capital Medical University ,Beijing Institute of Heart, Lung and Blood Vessel Diseases ,Beijing ,China
Song, Guangyuan;
Affiliation
Department of Anesthesiology ,Fuwai Hospital ,Chinese Academy of Medical Sciences and Peking Union Medical College ,Beijing ,China
Wang, Chunrong;
Affiliation
Department of Anesthesiology ,Fuwai Hospital ,Chinese Academy of Medical Sciences and Peking Union Medical College ,Beijing ,China
Shi, Sheng;
Affiliation
State Key Laboratory of Cardiovascular Disease ,Department of Cardiology ,Fuwai Hospital ,National Center for Cardiovascular Disease ,Chinese Academy of Medical Science and Peking Union Medical College ,Beijing ,China
Zhao, Jie;
Affiliation
State Key Laboratory of Cardiovascular Disease ,Department of Cardiology ,Fuwai Hospital ,National Center for Cardiovascular Disease ,Chinese Academy of Medical Science and Peking Union Medical College ,Beijing ,China
Zhang, Hongliang;
Affiliation
State Key Laboratory of Cardiovascular Disease ,Department of Cardiology ,Fuwai Hospital ,National Center for Cardiovascular Disease ,Chinese Academy of Medical Science and Peking Union Medical College ,Beijing ,China
Wang, Moyang;
Affiliation
State Key Laboratory of Cardiovascular Disease ,Department of Cardiology ,Fuwai Hospital ,National Center for Cardiovascular Disease ,Chinese Academy of Medical Science and Peking Union Medical College ,Beijing ,China
Niu, Guannan;
Affiliation
State Key Laboratory of Cardiovascular Disease ,Department of Cardiology ,Fuwai Hospital ,National Center for Cardiovascular Disease ,Chinese Academy of Medical Science and Peking Union Medical College ,Beijing ,China
Zhou, Zheng;
Affiliation
Department of Anesthesiology ,Fuwai Hospital ,Chinese Academy of Medical Sciences and Peking Union Medical College ,Beijing ,China
Wang, Jianhui;
Affiliation
State Key Laboratory of Cardiovascular Disease ,Department of Cardiology ,Fuwai Hospital ,National Center for Cardiovascular Disease ,Chinese Academy of Medical Science and Peking Union Medical College ,Beijing ,China
Wu, Yongjian

Background: Aortic stenosis (AS) increases left ventricular afterload, leading to cardiac damage and heart failure (HF). Transcatheter aortic valve replacement (TAVR) is an effective therapy for AS. No inotropic agents including levosimendan have been evaluated in patients undergoing TAVR. Methods: A total of 285 patients underwent TAVR between 2014 and 2019; 210 were included in the matched analysis and 105 received 0.1 μg/kg body weight/min levosimendan immediately after the prosthesis had been successfully implanted. Medical history, laboratory tests, and echocardiography results were analyzed. Endpoints including 2-year all-cause mortality, stroke, or HF-related hospitalization, and a combination of the above were analyzed by Cox proportional hazard models. Results: The levosimendan group had no difference in 2-year mortality compared with the control group (hazard ratio [HR]: 0.603, 95% confidence interval [CI]: 0.197–1.844; p = 0.375). However, levosimendan reduced stroke or HF-related hospitalization (HR: 0.346; 95% CI: 0.135–0.884; p = 0.027) and the combined endpoint (HR: 0.459, 95% CI: 0.215–0.980; p = 0.044). After adjusting for multiple variants, levosimendan still reduced stroke or HF-related hospitalization (HR: 0.346, 95% CI: 0.134–0.944; p = 0.038). Conclusion: Prophylactic levosimendan administration immediately after valve implantation in patients undergoing TAVR can reduce stroke or HF-related hospitalization but does not lower all-cause mortality.

Cite

Citation style:
Could not load citation form.

Access Statistic

Total:
Downloads:
Abtractviews:
Last 12 Month:
Downloads:
Abtractviews:

Rights

License Holder: Copyright © 2022 Zhao, Meng, Song, Wang, Shi, Zhao, Zhang, Wang, Niu, Zhou, Wang and Wu.

Use and reproduction: